1. Home
  2. Labeler Index
  3. Nucare Pharmaceuticals,inc.
  4. 68071-4974
  5. Product Images: Carvedilol

Product Images Carvedilol

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Carvedilol NDC 68071-4974 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PDP - 68071 4974 3

PDP - 68071 4974 3

This is a description of a medication for Carvedilol 3.125mg produced by Care Pharmaceuticals, Inc. The medication contains 30 tablets per bottle, has an expiration date of 00-00, and is only available by prescription. The tablets are coated in white and have an oval shape with the 'E' debossed on one side and lot number 000000 printed on the other. The medication comes with a warning to keep it out of children's reach, and the bottle should be stored at a controlled temperature of 68-77°F. If there are any side effects after taking the medication, one should contact a medical professional or report the side effects to the FDA.*

Figure 1. Survival Analysis for COPERNICUS (Intent-to-Treat) - carvedilol fig1

Figure 1. Survival Analysis for COPERNICUS (Intent-to-Treat) - carvedilol fig1

Figure 2. Effects on Mortality for Subgroups in COPERNICUS - carvedilol fig2

Figure 2. Effects on Mortality for Subgroups in COPERNICUS - carvedilol fig2

This is a figure from a study named COPERNICUS which shows the effects of a treatment on mortality rates for different subgroups. The subgroups include men and women, different age ranges, diabetic and non-diabetic patients, ischemic and non-ischemic patients, heart rate and blood pressure levels, and those who received the treatment versus those who did not. The Hazard ratio is also presented, which is a measure of the likelihood of an event occurring in one group compared to another. There is no available information about what treatment is being studied or what the actual hazard ratios are.*

Figure 3. Survival Analysis for CAPRICORN (Intent-to-Treat) - carvedilol fig3

Figure 3. Survival Analysis for CAPRICORN (Intent-to-Treat) - carvedilol fig3

Figure 4. Effects on Mortality for Subgroups in CAPRICORN - carvedilol fig4

Figure 4. Effects on Mortality for Subgroups in CAPRICORN - carvedilol fig4

Chemical Structure - carvedilol str

Chemical Structure - carvedilol str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.